Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Average (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Equity Average readings, the most recent being $586.6 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 30.96% to $586.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $586.6 million, a 30.96% increase, with the full-year FY2025 number at $503.0 million, up 14.68% from a year prior.
  • Equity Average hit $586.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $551.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $586.6 million in Q1 2026 to a low of $159.9 million in Q2 2022.
  • Median Equity Average over the past 5 years was $433.5 million (2024), compared with a mean of $408.2 million.
  • Biggest five-year swings in Equity Average: plummeted 39.71% in 2022 and later skyrocketed 150.75% in 2023.
  • Kiniksa Pharmaceuticals International's Equity Average stood at $390.1 million in 2022, then rose by 8.18% to $422.0 million in 2023, then increased by 3.73% to $437.7 million in 2024, then rose by 25.99% to $551.5 million in 2025, then rose by 6.37% to $586.6 million in 2026.
  • The last three reported values for Equity Average were $586.6 million (Q1 2026), $551.5 million (Q4 2025), and $515.2 million (Q3 2025) per Business Quant data.